Design of antiandrogens and their mechanisms of action: a case study (anandron).
The design of a new drug is conditioned by knowledge of the biochemical mechanisms involved in the etiology of the disease to be treated. With regard to endocrine pathologies, such knowledge can be obtained in the clinic from systematic assays of urinary and plasma hormones, enzyme activities and target tissue receptor concentrations. The present paper describes the results of our assays of plasma 3 alpha-androstanediol glucuronide, 5 alpha-reductase and androgen receptor in prostate cancer patients. The activity of the nonsteroid antiandrogen anandron is discussed in relation to these parameters: anandron may inhibit slightly adrenal androgen biosynthesis but, in particular, counters the action of these adrenal androgens on the prostate. It does not inhibit rat prostate 5 alpha-reductase activity but interacts with androgen receptor to exert an antiandrogen action.
Raynaud
J P
JP
Roussel-Uclaf, Paris, France.
Fiet
J
J
Le Goff
J M
JM
Martin
P M
PM
Moguilewsky
M
M
Ojasoo
T
T
D000726:Androgen Antagonists / Q000494:pharmacology*; D000728:Androgens / Q000378:metabolism*; D000818:Animals; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D048289:Imidazolidines; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011944:Receptors, Androgen / Q000187:drug effects / Q000378:metabolism
D000726:Androgen Antagonists; D000728:Androgens; D007093:Imidazoles; D048289:Imidazolidines; D011944:Receptors, Androgen; C021277:nilutamide